Schroder Investment Management Group lifted its stake in Eli Lilly and Company (NYSE:LLY – Get Rating) by 17.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,983,604 shares of the company’s stock after buying an additional 298,659 shares during the period. Eli Lilly and comprises approximately 0.7% of Schroder Investment Management Group’s holdings, making the stock its 25th largest holding. Schroder Investment Management Group’s holdings in Eli Lilly and were worth $547,910,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently modified their holdings of the company. AllSquare Wealth Management LLC acquired a new position in shares of Eli Lilly and in the 4th quarter worth approximately $28,000. Leverty Financial Group LLC bought a new position in Eli Lilly and in the 4th quarter valued at $29,000. Wagner Wealth Management LLC boosted its position in Eli Lilly and by 59.4% in the 3rd quarter. Wagner Wealth Management LLC now owns 110 shares of the company’s stock valued at $28,000 after buying an additional 41 shares during the last quarter. FSB Premier Wealth Management Inc. bought a new position in Eli Lilly and in the 4th quarter valued at $30,000. Finally, JFS Wealth Advisors LLC boosted its position in Eli Lilly and by 122.2% in the 4th quarter. JFS Wealth Advisors LLC now owns 120 shares of the company’s stock valued at $33,000 after buying an additional 66 shares during the last quarter. 82.75% of the stock is owned by institutional investors and hedge funds.
In related news, Director Marschall S. Runge bought 202 shares of the stock in a transaction that occurred on Tuesday, March 1st. The shares were acquired at an average price of $246.78 per share, with a total value of $49,849.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 700 shares of Eli Lilly and stock in a transaction dated Wednesday, May 18th. The stock was sold at an average price of $302.00, for a total value of $211,400.00. Following the transaction, the insider now owns 105,472,666 shares of the company’s stock, valued at approximately $31,852,745,132. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,169,012 shares of company stock worth $332,350,306. 0.12% of the stock is owned by company insiders.
Eli Lilly and (NYSE:LLY – Get Rating) last released its quarterly earnings results on Thursday, April 28th. The company reported $2.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.32 by $0.30. Eli Lilly and had a return on equity of 97.58% and a net margin of 20.90%. The firm had revenue of $7.81 billion for the quarter, compared to the consensus estimate of $7.29 billion. During the same quarter last year, the business posted $1.87 EPS. The company’s revenue for the quarter was up 14.8% on a year-over-year basis. Analysts forecast that Eli Lilly and Company will post 8.25 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, June 10th. Investors of record on Monday, May 16th will be given a $0.98 dividend. This represents a $3.92 dividend on an annualized basis and a dividend yield of 1.31%. The ex-dividend date is Friday, May 13th. Eli Lilly and’s dividend payout ratio is currently 58.07%.
Several research analysts have recently issued reports on the company. Mizuho raised their price target on Eli Lilly and from $315.00 to $356.00 in a research report on Monday, May 2nd. Bank of America raised their price target on Eli Lilly and from $300.00 to $315.00 in a research report on Thursday, March 17th. Wells Fargo & Company raised their price target on Eli Lilly and from $280.00 to $305.00 in a research report on Friday, April 29th. StockNews.com lowered Eli Lilly and from a “strong-buy” rating to a “buy” rating in a research report on Saturday, April 30th. Finally, The Goldman Sachs Group raised their price target on Eli Lilly and from $234.00 to $264.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 12th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $302.56.
Eli Lilly and Profile (Get Rating)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
- Get a free copy of the StockNews.com research report on Eli Lilly and (LLY)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Will John Deere’s Earnings Help to Calm the Markets?
- Lowe’s Companies Has Not Bottomed
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.